– Study met both primary endpoints in patients with ER+/HER2- advanced or mBC – Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC – Elacestrant extended PFS in the overall population and the ESR1 mutation subgroup – Plans for […]